Altimmune, Inc.

Altimmune is a clinical-stage biotech developing pemvidutide, a GLP-1 dual-agonist candidate for obesity and metabolic diseases including alcohol use disorder (AUD) and NASH. The stock is down 28% over the past year and sits at the 11th percentile of its 52-week range.

• Revenue was zero last quarter with a -$0.18 EPS — this is a pre-revenue biotech; the equity value is entirely on the pemvidutide pipeline outcomes.
• Trades at 6,644x TTM sales on nominal revenue — meaningless multiple math; the valuation is a probability-weighted call on the pemvidutide AUD Phase 2 data due Q3.
• Pemvidutide AUD data due in Q3 is the specific catalyst worth watching — a positive readout differentiates ALT from the crowded GLP-1 field and could re-rate the equity dramatically.
• Zero insider transactions in the last 30 days at 11th percentile of 52-week range — clean absence of distributing signal at these lows suggests management sees the pipeline case intact.
• 52-week position 11th percentile with small $269M market cap — the tape has fully priced in a Q3 disappointment scenario, which creates asymmetric upside if the AUD data is clean.

August 11 Q2 earnings is procedural; the real catalyst is the Q3 pemvidutide AUD data readout that could either restart the story dramatically or extend the drawdown. Positive AUD signal is where the -28% T12M reverses hard; negative data or a delayed readout is where the tape breaks below $2. Pure catalyst-play biotech with real optionality at deep-value entry — the setup is binary and depends on Q3 data delivering.